Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
Shenzhen Salubris commits additional funding to continue research and development of novel, complex biologics First patient enrolled in RENEU-HF, the Phase 2 clinical trial of JK07 in heart failure with reduced ejection fraction (HFrEF) and…